Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03508609 | Safety and Potential Bioactivity of CLBS16 in Patients With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery Disease | PHASE2 | COMPLETED | 20 | — | — | Apr 19, 2018 | May 5, 2020 | Jan 8, 2021 | 2 | United States |
Coronary Flow Reserve (CFR) is a measure of coronary microvascular function.
| Arm | Type | Description |
|---|---|---|
| Autologous CD34 cells | EXPERIMENTAL | Open label active treatment arm. Subjects receive autologous CD34 cells. |
| Name | Type | Description |
|---|---|---|
| CLBS16 | BIOLOGICAL | GCSF-mobilized autologous CD34 cells |
Inclusion Criteria: * Men or women age ≥18 * History of and currently experiencing angina at least 3 times per week * No obstructive coronary artery disease * On stable medical therapy for 30 days prior to enrollment * Must agree to use a reliable and acceptable method of contraception for the dura...